Did you mean?
Search Results - Showing 0 - 12 Of 39
_manufacturing-autologus-ex-vivo-genetically-modified-cell-therapies-have-challenges-but-the-future-is-bright.webp "Review the supply chainnExamine the contributors of costsnSolution for industrial scale viral vector manufacturingnCell processing and viral transduction hubsnRapid analytics for product testingnBrighter future for patients with fitter cell therapiesnn--nnJoseph TarnowskinSVP, Cell & Gene Therapy, R&D Medicinal Science and TechnologynGSKnnPrior to his current role in CGT, Joe was the Senior Vice President of Biopharm CMC R&D.Before joining GSK in June, 2010, Joe was the Senior Vice")
⏲ 23 min 1 sec ✓ 19-Nov-2019
_chemistry-manufacturing-and-controls-cmc.webp "GARDP")
_development-and-delivery-of-pharmaceutical-products-cmc-mars-best-practices.webp "MaRS Startup Toolkit")
⏲ 1 hour 7 minutes 46 seconds 👁 30.2K
_panel-looking-forward-where-are-biopharmaceutical-manufacturers-going-and-how-should-we-get-there.webp "• Talking about the state of the biotech industry today: Which emerging trend will see the most growth?n• People and technology: How are these forces working together to grow and mature our industry?n• Discussing challenges in capacity planning, make-buy decisions, and supply chain managementn• What is the next big challenge and the next big opportunity facing our community? Are we ready for it?nn--nnModerator: nnPatrick Yang, Former EVP, Technical Operations, GenentechnnDr. Patrick Y. Y")
⏲ 22 min 19 sec ✓ 15-Dec-2016
_overview-of-post-approval-chemistry-manufacture-and-controls-cmc-changes-to-an-nda-redi-2020.webp "U.S. Food and Drug Administration")
⏲ 27 minutes 10 seconds 👁 3.5K
_peptides-cmc-development-for-nce-projects-quickly-explained.webp "Bachem")
_industrialization-of-car-t-therapies-autologous-vs-allogeneic-common-and-uncommon-hurdles.webp "Industry evolution at a glancenDonor Variability, the greatest source of variability for cell therapies. Thoughts on characterizing and accommodating this variabilitynProcess considerations for Autologous CAR and the importance of a good data ecosystem to provide insight and understanding to this highly complex therapeutic modalitynBrief introduction to Kyvernann--nnKaren WalkernChief Technology OfficernKyverna TherapeuticsnnKaren Walker, Chief Technology Officer, Kyverna Therapeutics. Karen b")
⏲ 19 min 36 sec ✓ 28-Nov-2022
_mastering-change-control-process-in-the-pharmaceutical-industry-a-step-by-step-guide.webp "Pharma Quality")
⏲ 18 minutes 17 seconds 👁 1.1K
_tour-of-manufacturing-facility-124-nexus-pharmaceuticals.webp "Nexus Pharmaceuticals, LLC")
_panel-live-modalities-and-the-future-of-biopharmaceutical-manufacturing.webp "What are some of the unique challenges and opportunities in commercializing live modalities like CAR-T?nWeighing the pros and cons of centralized versus decentralized production models for these new treatmentsnDiscussing how our industry’s quality culture informs these new products from R&D right through to the patientnOffering lessons learned from the first generation of cell and gene therapies. How will their example inform what we are doing now?nSetting timelines for the future: What ar")
⏲ 22 min 52 sec ✓ 31-Oct-2018
_manufacturing-of-api-active-pharmaceutical-ingredient.webp "Jatin Kumar Bollareddy")
_a-day-in-the-life-of-a-project-manager-124-indeed.webp "Indeed")
![[+]](/images/menu.gif){kind=small}